Acthar gel in the treatment of nephrotic syndrome: A multicenter retrospective case series

BMC Nephrology

Volumn 17, Issue 1, 2016, Pages

  Madan, Arvind ^a   Mijovic Das, Snezana ^b   Stankovic, Ana ^c   Teehan, Geoffrey ^d   Milward, Amber S ^a   Khastgir, Anupa ^e  

^a Nephrology Associates of Central Florida   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c HCA Inc Physician Services   (United States)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e Nephrology Practice   (United States)

Author keywords

ACTH; Acthar gel; Nephrotic syndrome; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; GEL; HORMONE;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SEIZURE; SWELLING; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; AGED; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; GEL; LIPOID NEPHROSIS; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; COHORT STUDIES; DIABETIC NEPHROPATHIES; FEMALE; GELS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HORMONES; HUMANS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; PROTEINURIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85008422671     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-016-0241-7     Document Type: Article

References (26)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.
2. Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Trachtman H, Waldman M. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013;62:403-41.
3. Segarra-Medrano A, Jatem-Escalante E, Agraz-Pamplona I, Carnicer-Caceres C, Ramos-Terrades N, Ostos-Roldan E, Quiles-Perez MT, Arbos-Via MA. Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors. Nefrologia. 2013;33:448-61.
4. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445-53.
5. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694-701.
6. Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177-83.
7. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797-808.
8. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-60.
9. Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol. 2008;4:550-9.
10. H.P. Acthar® Gel (repository corticotropin injection) [prescribing information]. Hazelwood: Mallinckrodt ARD Inc.; 2015.
11. Rapoport M, McCrory WW, Barbero G, Barnett HL, Forman CW. Effect of corticotropin (ACTH) on children with the nephrotic syndrome. JAMA. 1951;147:1101-6.
12. Durand P, DeToni Jr E. Treatment of nephrotic syndrome in children. An Paediatr. 1955;185:225-35.
13. Gong R. Leveraging melanocortin pathways to treat glomerular diseases. Adv Chronic Kidney Dis. 2014;21:134-51.
14. Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, Radhakrishnan J, Appel GB. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011;5:147-53.
15. Bomback AS, Canetta PA, Beck Jr LH, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36:58-67.
16. Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013;8:2072-81.
17. Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. J Diabetes Res. 2013;2013:489869.
18. Watson MJ. Membranous glomerulopathy and treatment with Acthar®: a case study. Int J Nephrol Renovasc Dis. 2013;6:229-32.
19. Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29:1570-7.
20. Lieberman KV, Ettinger L, Picarelli C: Adrenocorticotropic hormone for steroid-resistant and oral steroid-intolerant children with minimal change nephrotic syndrome. J Clin Pediatr Nephrol 2014, 2: http://www. jpnephrology.com/index.php/FIRST/article/view/64.
21. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061-8.
22. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66:1199-205.
23. Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9:443-58.
24. Lindskog A, Ebefors K, Johansson ME, Stefansson B, Granqvist A, Arnadottir M, Berg AL, Nystrom J, Haraldsson B. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21:1290-8.
25. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2012;8:122-8.
26. Gong R, Dworkin LD. Adrenocorticotropin (ACTH) gel suppresses renal tubulointerstitial inflammation and injury by direct stimulation of the melanocortin 1 receptor (MC1R) [abstract]. J Am Soc Nephrol. 2011;22(suppl):136A.